STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with the Menarini Group’s subsidiary RELIFE. The first half of this year has been an intensive period in several areas. In the beginning of the year, we signed a license agreement with Cannassure Therapeutics […]
STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, […]
STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Lipidor (publ) (the “Company”) on 8 June 2021. Due to the covid-19 pandemic, the Company’s extraordinary general meeting was carried out through advance voting (postal voting) only. Incentive programme in the subsidiary Emollivet AB The EGM resolved, […]
STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor (publ) (the “Company”) on 8 June 2021. Due to the covid-19 pandemic, the Company’s annual general meeting was carried out through advance voting (postal voting) only. Adoption of income statement and balance sheet and discharge from […]
STOCKHOLM, Sweden, 24 May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company” or “Lipidor”) are hereby given notice of the Extraordinary General Meeting (the “EGM”) to be held on 8 June 2021. N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall […]
STOCKHOLM, Sweden, 7th May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 8 June 2021. N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall […]
STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The quarterly report is available on the company's website (click here (https://lipidor.se/lipidor-ab-delrsrapport-q1-2021/)) and in the attached pdf (in Swedish). Summary of the interim report – first quarter 2021 The period began with a […]
Stockholm, Sweden, 23 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that the company will publish its annual report for the financial year 2020. The annual report (in Swedish) is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-rsredovisning-2020/) and in the attached pdf. The information was submitted for publication, through the office of […]
Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch. Emollivet develops […]
Stockholm, Sweden, 22 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase […]